Anti-cancer drugs-induced arterial injury: risk stratification, prevention, and treatment

Edit Gara, Kristóf György Csikó, Zoltán Ruzsa, Gábor Földes, B. Merkely

Research output: Contribution to journalReview article

Abstract

Vascular side effects of standard chemotherapeutic drugs and novel anti-tumor agents complicate treatment cycles, increase non-cancer-related mortality rates, and decrease the quality of life in cancer survivors. Arterial thromboembolic events (ATEE) are associated with most anti-cancer medications. Previous articles have reported a variety of vascular events including ST-segment elevation myocardial infarction as one of the most severe acute arterial attacks. Cardiologists should play an early role in identifying those at high risk for vascular complications and tailor anti-thrombotic therapies in keeping with thromboembolic and bleeding risks. Early preventive steps and individualized chemotherapy may decrease anti-tumor treatment-related vascular events. Here, we aim to provide an extensive review of anti-tumor drug-induced vascular injury (DIVI), pathomechanisms, and risk stratification underlining arterial events. We give a summary of clinical manifestations, treatment options, and possible preventive measures of DIVI. Additionally, the treatment of modifiable risk factors and tailored choice of chemotherapy must be considered in all oncology patients to prevent DIVI. We propose a complex tool for ATEE risk stratification which is warranted for early prediction leading to less frequent complications in cancer patients.

Original languageEnglish
Article number72
JournalMedical Oncology
Volume36
Issue number8
DOIs
Publication statusPublished - Aug 1 2019

Fingerprint

Blood Vessels
Vascular System Injuries
Wounds and Injuries
Pharmaceutical Preparations
Neoplasms
Therapeutics
Drug Therapy
Survivors
Quality of Life
Hemorrhage
Mortality

Keywords

  • Anti-cancer treatment
  • Drug-induced vascular injury
  • Prevention
  • Risk stratification
  • Thromboembolic events

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Anti-cancer drugs-induced arterial injury : risk stratification, prevention, and treatment. / Gara, Edit; Csikó, Kristóf György; Ruzsa, Zoltán; Földes, Gábor; Merkely, B.

In: Medical Oncology, Vol. 36, No. 8, 72, 01.08.2019.

Research output: Contribution to journalReview article

Gara, Edit ; Csikó, Kristóf György ; Ruzsa, Zoltán ; Földes, Gábor ; Merkely, B. / Anti-cancer drugs-induced arterial injury : risk stratification, prevention, and treatment. In: Medical Oncology. 2019 ; Vol. 36, No. 8.
@article{6c8c7f4ec20f4d5caeb224064288b32e,
title = "Anti-cancer drugs-induced arterial injury: risk stratification, prevention, and treatment",
abstract = "Vascular side effects of standard chemotherapeutic drugs and novel anti-tumor agents complicate treatment cycles, increase non-cancer-related mortality rates, and decrease the quality of life in cancer survivors. Arterial thromboembolic events (ATEE) are associated with most anti-cancer medications. Previous articles have reported a variety of vascular events including ST-segment elevation myocardial infarction as one of the most severe acute arterial attacks. Cardiologists should play an early role in identifying those at high risk for vascular complications and tailor anti-thrombotic therapies in keeping with thromboembolic and bleeding risks. Early preventive steps and individualized chemotherapy may decrease anti-tumor treatment-related vascular events. Here, we aim to provide an extensive review of anti-tumor drug-induced vascular injury (DIVI), pathomechanisms, and risk stratification underlining arterial events. We give a summary of clinical manifestations, treatment options, and possible preventive measures of DIVI. Additionally, the treatment of modifiable risk factors and tailored choice of chemotherapy must be considered in all oncology patients to prevent DIVI. We propose a complex tool for ATEE risk stratification which is warranted for early prediction leading to less frequent complications in cancer patients.",
keywords = "Anti-cancer treatment, Drug-induced vascular injury, Prevention, Risk stratification, Thromboembolic events",
author = "Edit Gara and Csik{\'o}, {Krist{\'o}f Gy{\"o}rgy} and Zolt{\'a}n Ruzsa and G{\'a}bor F{\"o}ldes and B. Merkely",
year = "2019",
month = "8",
day = "1",
doi = "10.1007/s12032-019-1295-8",
language = "English",
volume = "36",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "8",

}

TY - JOUR

T1 - Anti-cancer drugs-induced arterial injury

T2 - risk stratification, prevention, and treatment

AU - Gara, Edit

AU - Csikó, Kristóf György

AU - Ruzsa, Zoltán

AU - Földes, Gábor

AU - Merkely, B.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Vascular side effects of standard chemotherapeutic drugs and novel anti-tumor agents complicate treatment cycles, increase non-cancer-related mortality rates, and decrease the quality of life in cancer survivors. Arterial thromboembolic events (ATEE) are associated with most anti-cancer medications. Previous articles have reported a variety of vascular events including ST-segment elevation myocardial infarction as one of the most severe acute arterial attacks. Cardiologists should play an early role in identifying those at high risk for vascular complications and tailor anti-thrombotic therapies in keeping with thromboembolic and bleeding risks. Early preventive steps and individualized chemotherapy may decrease anti-tumor treatment-related vascular events. Here, we aim to provide an extensive review of anti-tumor drug-induced vascular injury (DIVI), pathomechanisms, and risk stratification underlining arterial events. We give a summary of clinical manifestations, treatment options, and possible preventive measures of DIVI. Additionally, the treatment of modifiable risk factors and tailored choice of chemotherapy must be considered in all oncology patients to prevent DIVI. We propose a complex tool for ATEE risk stratification which is warranted for early prediction leading to less frequent complications in cancer patients.

AB - Vascular side effects of standard chemotherapeutic drugs and novel anti-tumor agents complicate treatment cycles, increase non-cancer-related mortality rates, and decrease the quality of life in cancer survivors. Arterial thromboembolic events (ATEE) are associated with most anti-cancer medications. Previous articles have reported a variety of vascular events including ST-segment elevation myocardial infarction as one of the most severe acute arterial attacks. Cardiologists should play an early role in identifying those at high risk for vascular complications and tailor anti-thrombotic therapies in keeping with thromboembolic and bleeding risks. Early preventive steps and individualized chemotherapy may decrease anti-tumor treatment-related vascular events. Here, we aim to provide an extensive review of anti-tumor drug-induced vascular injury (DIVI), pathomechanisms, and risk stratification underlining arterial events. We give a summary of clinical manifestations, treatment options, and possible preventive measures of DIVI. Additionally, the treatment of modifiable risk factors and tailored choice of chemotherapy must be considered in all oncology patients to prevent DIVI. We propose a complex tool for ATEE risk stratification which is warranted for early prediction leading to less frequent complications in cancer patients.

KW - Anti-cancer treatment

KW - Drug-induced vascular injury

KW - Prevention

KW - Risk stratification

KW - Thromboembolic events

UR - http://www.scopus.com/inward/record.url?scp=85068780149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068780149&partnerID=8YFLogxK

U2 - 10.1007/s12032-019-1295-8

DO - 10.1007/s12032-019-1295-8

M3 - Review article

C2 - 31292791

AN - SCOPUS:85068780149

VL - 36

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 8

M1 - 72

ER -